Fujifilm

Fujifilm is the principal international brand of Fujifilm Holdings Corporation, a Japanese multinational technology group headquartered in Tokyo. The company was established in 1934 as Fuji Photo Film, a subsidiary of Daicel, to manufacture photographic film for the Japanese market. Photography remains part of the business, but Fujifilm has spent decades applying its expertise in chemistry, precision coating, optics, electronics, image processing, and materials engineering to sectors well beyond consumer cameras. Its current activities span photographic film and paper, digital cameras and lenses, instant photography, optical devices, document and workplace technology, graphic-arts equipment, medical imaging, healthcare information systems, pharmaceuticals, biopharmaceutical contract development and manufacturing, regenerative medicine, specialty chemicals, display materials, and magnetic data-storage media. The group also supplies technologies used in television lenses, flat-panel displays, printing, radiography, endoscopy, ultrasound, and laboratory and manufacturing workflows. Fujifilm’s photography portfolio is led by the X Series of interchangeable-lens cameras and lenses, the GFX line of large-sensor medium-format cameras, and the Instax ecosystem of instant cameras, printers, and film. It also continues to sell selected color negative, slide, and black-and-white films, including Fujicolor, Fujichrome, and Neopan products. These businesses serve both professional users and enthusiasts, with product differentiation built around image quality, color science, compact design, optical performance, and film-inspired workflows. The company’s strategic identity changed substantially as digital imaging reduced demand for traditional photographic film. Rather than relying solely on the shrinking film market, Fujifilm used its accumulated know-how in thin-film coating, emulsions, diagnostics, chemicals, and imaging to diversify into healthcare, electronic materials, printing, and life sciences. Its computed-radiography technology and later digital medical systems helped establish a substantial healthcare presence. Acquisitions and investments expanded its diagnostic-imaging, biologics manufacturing, and pharmaceutical capabilities. A major organizational transition occurred in 2006, when Fuji Photo Film became part of a holding-company structure and adopted the Fujifilm Holdings name. The former Fuji Xerox relationship with Xerox was progressively unwound: Fujifilm acquired Xerox’s interest in the joint venture in 2019, and the business was renamed Fujifilm Business Innovation in 2021. This left Fujifilm with a wholly owned business-technology operation alongside its imaging, healthcare, materials, and life-science businesses. Today, Fujifilm operates internationally through a large network of subsidiaries and regional companies. It is simultaneously a consumer-facing photography brand, a supplier of professional imaging and printing systems, and a business-to-business technology group. Its transformation from film manufacturer to diversified technology company is the defining feature of its modern positioning.

Fuji Photo Film was founded in 1934 as a Daicel subsidiary to produce photographic film in Japan. During the 1940s it broadened its technical base into optical glass, lenses, and related equipment. From the mid-1950s onward, the company created overseas sales operations, followed by international manufacturing and other facilities during the 1980s. The postwar business initially centered on film, photographic paper, cameras, processing, and optical products. Fujifilm competed with Kodak in a market shaped by strong national positions and extensive distribution networks. Its sponsorship of the 1984 Los Angeles Olympic Games, lower-priced film offerings, and establishment of manufacturing capacity in the United States helped increase its visibility and market share there. At the same time, Fujifilm invested in digital technologies. It adapted imaging and materials expertise to medical and printing applications and developed computed radiography, marketed through its FCR systems. This technology replaced parts of the conventional radiographic workflow with photostimulable plates and digital processing, helping reduce some limitations associated with traditional X-ray methods. The company faced a serious corporate-ethics episode in the 1990s. In 1994, vice president Juntaro Suzuki said Fujifilm would stop paying sokaiya, individuals who used threats or disruption to extract payments from companies. Suzuki was later killed outside his home. The episode became part of the company’s public history and Japan’s broader debate about corporate links to organized crime. In 1995, Kodak challenged Fujifilm’s competitive position in Japan through a petition under section 301 of the United States trade law. The United States brought the dispute to the World Trade Organization. In 1998, the WTO rejected Kodak’s central complaints about the Japanese photographic-film market. Fujifilm continued diversifying as digital photography weakened demand for traditional film. It expanded in document technology, graphic arts, medical imaging, electronic materials, data storage, pharmaceuticals, and biotechnology. In 1962 it had established Fuji Xerox with Rank Xerox, creating a long-lived document-technology partnership. In 2005 it acquired Sericol, a printing-ink business, and in 2006 announced a strategic relationship with Noritsu concerning photofinishing hardware. A holding-company reorganization announced in 2006 placed Fujifilm and Fuji Xerox under Fujifilm Holdings Corporation. The group later pursued a larger Xerox transaction, announcing in 2018 a proposed acquisition of a controlling stake in Xerox. Investor opposition led to the proposal being abandoned. In 2019 Fujifilm instead acquired Xerox’s remaining interest in Fuji Xerox. The business was renamed Fujifilm Business Innovation, effective in 2021. Healthcare and life sciences became increasingly important areas of expansion. Fujifilm acquired Hitachi’s diagnostic-imaging business in 2019 and invested in biologics manufacturing capacity in Denmark in 2020. Its pharmaceutical subsidiary’s favipiravir product, Avigan, received international attention during the COVID-19 pandemic, although its role was subject to regulatory review and continuing clinical evaluation. Fujifilm remains active in conventional film while operating a much broader portfolio. Its modern identity combines consumer and professional photography with healthcare systems, advanced materials, business technology, printing, storage media, and biopharmaceutical manufacturing.

1. 2021Fuji Xerox becomes Fujifilm Business Innovation

   The former Fuji Xerox operation adopts its new Fujifilm Business Innovation identity.

   Source
2. 2019Xerox stake in Fuji Xerox acquired

   Fujifilm acquires Xerox’s remaining 25 percent interest in Fuji Xerox.

   Source
3. 2019Hitachi diagnostic-imaging business acquired

   Fujifilm acquires Hitachi’s diagnostic-imaging business, strengthening its healthcare portfolio.

   Source
4. 2006Holding-company reorganization announced

   Fujifilm announces the creation of Fujifilm Holdings, with Fujifilm and Fuji Xerox as operating subsidiaries.

   Source
5. 1998WTO rejects Kodak complaints

   The WTO rejects Kodak’s complaints concerning Fujifilm and access to Japan’s photographic-film market.

   Source
6. 1994Anti-sokaiya stance and executive murder

   Vice president Juntaro Suzuki announces an end to payments to sokaiya and is later murdered.

   Source
7. 1984Los Angeles Olympics sponsorship

   Fujifilm becomes a title sponsor of the Los Angeles Olympic Games, supporting its expansion of film sales in the United States.

   Source
8. 1962Fuji Xerox joint venture begins

   Fuji Photo Film and Rank Xerox establish Fuji Xerox for document and office technology.

   Source
9. 1940Expansion into optics

   The company enters optical glass, lenses, and optical equipment during the 1940s.

   Source
10. 1934Fuji Photo Film is established

    Fuji Photo Film Co. is founded as a subsidiary of Daicel to manufacture photographic film.

    Source

A science- and technology-driven imaging and information-solutions group combining photographic heritage with healthcare, advanced materials, business technology, and life sciences.

• Fujifilm X SeriesAPS-C digital cameras and lenses

  The X Series is Fujifilm’s principal interchangeable-lens camera platform for enthusiast and professional photographers. It uses APS-C sensors across its current camera range and is supported by Fujinon lenses, dedicated accessories, and Fujifilm’s distinctive color-processing and film-simulation features. The line includes compact rangefinder-inspired bodies, weather-resistant cameras, and models aimed at street, travel, documentary, studio, and video work.

• Fujifilm GFX SeriesMedium-format digital cameras

  GFX is Fujifilm’s large-sensor medium-format digital-camera system. It targets commercial, fashion, landscape, studio, and high-resolution content creation through large sensors, interchangeable GF lenses, and bodies designed for both still photography and video. The system extends Fujifilm’s professional imaging business above the APS-C X Series.

• InstaxInstant photography

  Instax is Fujifilm’s instant-photography ecosystem, comprising analog instant cameras, hybrid and digital models, smartphone-connected printers, and instant film. Film formats include Mini, Square, and Wide. Instax serves casual consumers, younger users, creative communities, events, and users seeking physical photographs alongside digital imaging.

• Fujifilm photographic filmPhotographic film and paper1934

  Fujifilm continues to produce selected color negative, color reversal, and black-and-white films. Notable families include Fujicolor, Fujichrome Velvia, Fujichrome Provia, and Neopan ACROS. The company also supplies photographic paper and related materials for professional, laboratory, archival, and enthusiast workflows.

• Fujinon lenses and optical devicesOptics

  Fujinon is Fujifilm’s optical brand covering interchangeable camera lenses and professional optical products. Its technologies also support television and broadcast lenses, binoculars, industrial optics, and other precision imaging applications. Fujinon lenses are used across the X and GFX camera systems and in professional production environments.

• Fujifilm medical imaging systemsHealthcare technology

  Fujifilm’s healthcare portfolio includes computed and digital radiography, mammography, endoscopy, ultrasound, diagnostic imaging, and healthcare information systems. The FCR computed-radiography platform helped the company transfer its imaging and materials expertise into clinical workflows, while Synapse products provide systems for radiology and cardiovascular information management.

• Fujifilm Business InnovationDocument and workplace technology1962

  Fujifilm Business Innovation is the group’s document-technology operation, developed from the former Fuji Xerox relationship. It provides multifunction printers, production printers, office workflows, document management, and related services for businesses and public-sector organizations.

• Fujifilm Diosynth BiotechnologiesBiopharmaceutical services

  Fujifilm Diosynth Biotechnologies provides contract development and manufacturing services for biologics, vaccines, and other advanced therapies. It forms part of Fujifilm’s life-sciences diversification and supports clients through development, process work, and commercial-scale manufacturing.

• Magnetic data-storage tapeData storage

  Fujifilm manufactures magnetic tape for data storage and archival applications. Its recording-media expertise developed from the company’s broader history in coated films and precision materials, and the business serves organizations requiring high-capacity, long-term data preservation.

• 1984Los Angeles Olympic Games sponsorship

  United States · International

  Fujifilm used sponsorship of the 1984 Los Angeles Olympic Games to raise brand recognition and support its expansion in the United States photographic-film market.

  Outcome. The sponsorship contributed to international visibility during an important period of overseas expansion.

  Source

• 2020Expand Danish biologics manufacturing capacityStrategy

  Fujifilm was expanding its life-sciences and biopharmaceutical manufacturing platform.

  What changed. The company announced an investment of approximately US$928 million in a Danish biologics facility acquired from Biogen.

  Aftermath. The planned investment was intended to double the facility’s manufacturing capacity.

  Announced investment. US$928 million (2020 announcement)

  Source
• 2019Acquire Xerox’s remaining Fuji Xerox stakeM&A

  After the proposed Xerox combination was abandoned, Fujifilm pursued full ownership of the long-running document-technology joint venture.

  What changed. Fujifilm acquired Xerox’s 25 percent interest in Fuji Xerox.

  Aftermath. Fuji Xerox became wholly owned by Fujifilm and was later renamed Fujifilm Business Innovation.

  Source
• 2019Acquire Hitachi’s diagnostic-imaging businessM&A

  Fujifilm sought to strengthen its healthcare and medical-imaging activities.

  What changed. Fujifilm acquired Hitachi’s diagnostic-imaging business.

  Aftermath. The acquisition expanded Fujifilm’s diagnostic-imaging portfolio and healthcare capabilities.

  Source
• 2018Proposed acquisition of XeroxM&A

  Fujifilm sought to combine Xerox with the existing Fuji Xerox joint venture and obtain a controlling interest in the enlarged business.

  What changed. Fujifilm announced a proposed transaction valued at approximately US$6.1 billion, but the proposal was later abandoned after opposition from Xerox investors.

  Aftermath. Fujifilm subsequently acquired Xerox’s remaining stake in Fuji Xerox in 2019 instead of completing the proposed combination.

  Proposed transaction value. (2018 proposed transaction)

  Source
• 2006Create a holding-company structureStrategy

  Fujifilm was managing a portfolio that included photography, document technology, healthcare, and materials businesses while traditional film demand was changing.

  What changed. The company announced Fujifilm Holdings Corporation as the umbrella structure for Fujifilm and Fuji Xerox.

  Aftermath. The reorganization supported the group’s long-term diversification beyond photographic film.

  Source

• 1994Juntaro Suzuki murder and the sokaiya issueControversy

  Vice president Juntaro Suzuki announced that Fujifilm would stop paying sokaiya, corporate extortionists associated with organized crime. He was murdered outside his home after the announcement. The incident became a prominent corporate-governance and organized-crime controversy connected with the company.

  Source

• 2025Fujifilm completed the acquisition of Pacific Business Consulting

  FUJIFILM Digital Solutions completed the acquisition of Pacific Business Consulting, a Microsoft Dynamics 365 sales and implementation consultancy, expanding the group’s business-systems integration capabilities.

  M&A
  Source
• 2022Fujifilm expanded its semiconductor-materials business through a U.S. acquisition

  Fujifilm announced the acquisition of CMC Materials’ KMG Corporation business from Entegris, adding chemicals used in semiconductor cleaning and related manufacturing processes.

  M&A
  Source
• 2022Fujifilm continues expansion of the Instax instant-photography ecosystem

  The company continued introducing Instax cameras, printers, film formats, and hybrid digital-analog products as part of its consumer imaging strategy.

  Product launchProduct generation
  Source
• 2021Fuji Xerox is renamed Fujifilm Business Innovation

  The former Fuji Xerox business adopted the Fujifilm Business Innovation name as the companies’ joint-venture relationship ended.

  Leadership change
  Source
• 2021Fujifilm reorganizes its document solutions business after the end of the Xerox joint venture

  Following the end of the Xerox joint venture, Fujifilm reorganized its document-related operations under the Fujifilm Business Innovation structure.

  M&A
  Source
• 2020Fujifilm expands biologics manufacturing capacity in Denmark

  Fujifilm announced a major investment in a Danish biologics production facility acquired from Biogen, with the stated aim of substantially increasing manufacturing capacity.

  Other
  Source
• 2020Fujifilm’s Avigan attracts attention during the COVID-19 pandemic

  Favipiravir, marketed by a Fujifilm pharmaceutical subsidiary as Avigan, was considered and used in some countries in connection with COVID-19 treatment research and emergency responses.

  RegulationOther
  Source
• 2020Fujifilm expands biologics manufacturing through strategic acquisitions

  Fujifilm expanded its biopharmaceutical manufacturing platform through transactions involving Biogen's biologics manufacturing operations and related assets.

  M&A
  Source
• 2019Fujifilm acquires Xerox’s interest in Fuji Xerox

  Fujifilm announced the purchase of Xerox’s 25 percent stake in the long-running joint venture, making the business wholly owned by Fujifilm.

  M&A
  Source
• 2019Fujifilm acquired Hitachi’s diagnostic imaging business

  Fujifilm agreed to acquire Hitachi’s diagnostic imaging operations, including MRI, CT, and ultrasound activities, to strengthen its healthcare platform and combine medical equipment with image-processing and artificial-intelligence capabilities.

  M&A
  Source
• 2019Fujifilm made Fuji Xerox a wholly owned subsidiary

  Fujifilm acquired Xerox’s remaining interest in Fuji Xerox and agreed to a new relationship, enabling the document-solutions business to operate fully within the Fujifilm group.

  M&A
  Source
• 2019Fujifilm completes acquisition of Hitachi's diagnostic imaging business

  Fujifilm completed the acquisition of Hitachi's diagnostic imaging business, expanding its portfolio in medical imaging and strengthening its healthcare strategy.

  M&A
  Source
• 2018Fujifilm announces plan to acquire a controlling stake in Xerox

  Fujifilm announced a proposed transaction that would have combined Xerox with the existing Fuji Xerox joint venture. The transaction was later abandoned after opposition from Xerox investors.

  M&A
  Source
• 2018Fujifilm ends the proposed Xerox combination

  The planned Xerox transaction was withdrawn following intervention by activist investors Carl Icahn and Darwin Deason.

  M&A
  Source
• 2018Fujifilm launched a global corporate campaign built around “NEVER STOP”

  The campaign presented Fujifilm’s transformation from a film-centered company into a diversified healthcare, advanced-materials, imaging, and document-solutions group.

  Campaign
  Source
• 1995Kodak challenges Fujifilm’s position in Japan’s film market

  Kodak petitioned the United States government over alleged unfair conditions affecting its performance in Japan. The dispute reached the World Trade Organization, which rejected Kodak’s complaints in 1998.

  LawsuitRegulation
  Source

1. Fujifilm
2. Fujifilm official website
3. Fujifilm completed the acquisition of Pacific Business Consulting
4. Fujifilm expanded its semiconductor-materials business through a U.S. acquisition
5. Fujifilm continues expansion of the Instax instant-photography ecosystem
6. Fujifilm reorganizes its document solutions business after the end of the Xerox joint venture
7. Fujifilm acquired Hitachi’s diagnostic imaging business
8. Fujifilm made Fuji Xerox a wholly owned subsidiary
9. Fujifilm launched a global corporate campaign built around “NEVER STOP”